Higher output of AR signaling, based on higher serum PSA levels and higher levels of AR transcripts in circulating tumor cells, were suggested to be a potential marker of better SPT response in clinical trials, and our previous study findings also showed higher levels of AR and AR-signaling output in SPT-inhibited PC cell lines and PDXs (4, 6). The gene discussed is AR; the disease is pachyonychia congenita.